Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

NCT04272125 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL: CD123 CAR-T cells

Sponsor

Chongqing Precision Biotech Co., Ltd